Comparative Pharmacology
Head-to-head clinical analysis: SECTRAL versus ZIAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SECTRAL versus ZIAC.
SECTRAL vs ZIAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; negative chronotropic and inotropic effects, reduces cardiac output, decreases renin release.
ZIAC is a combination of bisoprolol, a cardioselective beta1-adrenergic receptor blocker, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing blood volume.
Adult: 200–400 mg orally once daily, initially; may increase to 400–800 mg daily in divided doses (e.g., 200 mg twice daily). Maximum 800 mg/day. Route: Oral.
ZIAC (bisoprolol fumarate/hydrochlorothiazide) 2.5 mg/6.25 mg to 10 mg/6.25 mg orally once daily, titrated at 2-week intervals based on blood pressure response. Maximum dose: 20 mg/12.5 mg per day.
None Documented
None Documented
Terminal elimination half-life: 8-13 hours; clinically, this supports once-daily dosing, but steady-state is achieved within 2-3 days.
Bisoprolol: 9–12 h (terminal); HCTZ: 6–15 h (terminal); prolonged in renal impairment; steady state by 5 days
Renal: ~30-40% unchanged; biliary/fecal: ~20-30% as metabolites and parent compound; total renal clearance accounts for 50-70% of elimination.
Renal: bisoprolol (50% unchanged), HCTZ (≥95% unchanged); biliary/fecal: bisoprolol (≤2%)
Category C
Category C
Beta Blocker
Beta Blocker + Diuretic